Monopar Therapeutics
MNPR
7 hedge funds and large institutions have $429K invested in Monopar Therapeutics in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.
17% more funds holding
Funds holding: 6 → 7 (+1)
6% more capital invested
Capital invested by funds: $403K → $429K (+$26K)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.02% less ownership
Funds ownership: 0.14% → 0.12% (-0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$4.9K |
| 3 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$878 |
| 4 |
Wells Fargo
San Francisco,
California
|
+$26 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$30.7K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Northern Trust
Chicago,
Illinois
| $360K | -$30.7K | -1,191 | -9% |
|
|
2
BlackRock
New York
| $33K | +$13.9K | +537 | +99% |
|
3
Morgan Stanley
New York
| $20K | – | – | – |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $9K | -$17K | -659 | -70% |
|
|
5
UBS Group
Zurich,
Switzerland
| $6K | +$4.9K | +190 | New |
|
|
6
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $1K | +$878 | +34 | New |
|
|
7
Wells Fargo
San Francisco,
California
| – | +$26 | +1 | +33% |
|
MNPR Hedge Fund Activity: Q4 2020 in Review
7 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q4 2020, worth a combined $429K — up 6.5% from $403K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new MNPR positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock, adding an estimated $13.9K. The largest seller was Northern Trust, cutting an estimated $30.7K.
- 7 institutional investors held Monopar Therapeutics (MNPR) as of Q4 2020, up from 6 in Q3 2020.
- Funds reported $429K of Monopar Therapeutics stock for Q4 2020, up 6.5% quarter-over-quarter.
- 2 funds opened new Monopar Therapeutics positions in Q4 2020 and 0 closed out, a net change of +2 holders.
- The largest Monopar Therapeutics buyer in Q4 2020 was BlackRock, an estimated $13.9K added.
- The largest Monopar Therapeutics seller in Q4 2020 was Northern Trust, an estimated $30.7K sold.
Based on aggregated 13F filings for Q4 2020.